Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib<sup>+</sup>

Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib<sup>+</sup>

The majority of breast cancers express the estrogen receptor (ER) and are dependent on estrogen for their growth and survival. Endocrine therapy (ET) is the standard of care for these tumors. However, a superior outcome is achieved in a subset of ER positive (ER<sup>+</sup>)/human epider...

Full description

Bibliographic Details
Main Authors: Nicla Lorito, Marina Bacci, Alfredo Smiriglia, Michele Mannelli, Matteo Parri, Giuseppina Comito, Luigi Ippolito, Elisa Giannoni, Martina Bonechi, Matteo Benelli, Ilenia Migliaccio, Luca Malorni, Paola Chiarugi, Andrea Morandi
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cells
Subjects:
palbociclib
metabolic reprogramming
breast cancer
warburg metabolism
resistance
Online Access:https://www.mdpi.com/2073-4409/9/3/668

Internet

https://www.mdpi.com/2073-4409/9/3/668

Similar Items